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Abstract. Prostacyclin is able to inhibit the development of platelet prothrombinase activi-
ty. This inhibition, which also occurs with dibutyryl cAMP, is presumably due to the ability of
prostacyclin to prevent the formation of a negatively charged phospholipiri surface at the exte-
rior half of the plateiet membrane. Generation of this procoagulant surface, as induced by
platelet activation with collagen plus thrombin, does not depend on thromboxane A,2 forma-
tion.
Inhoduction
In platelet rich plasma the reduction of the
recalcification time and Russell's viper ve-
nom time induced by kaolin or collagen can
be prevented by prostacyclin [1, 2]. These
results have been taken to indicate that pros-
tacyclin inhibits the development of platelel
factor 3 activity. This activity is defrned as
the ability of platelets to shorten the Russell's
viper venom-clotting time and therefore re-
fers to the prothrombin converting activity of
platelets.
Platelets can provide at least two compo-
nents for the prothrombinase complex: factor
V(Vj and negatively charged phospholipids
[3]. Factor V appears as a result ofthe platelet
release reaction [4, 5] and smali amounts of
thrombin can convert it to the activated form
factor V" [6]. This effect as such can drasti-
cally reduce the Russell's viper venom-clot-
ting time [7, 8], and is presumabiy related ro
the ability of factor Vu to create high affrnity
binding sites for factor X" on the platelet
outer surface [9-11]. We have previously
shown [12, 13] that activation of human
platelets, particularly by a mixture of colla-
gen and thrombin, is accompanied with in-
creased exposure ofnegatively charged phos-
phatidylserine in the outer leaflet of the
plasma membrane, resulting from induced
transbilayer movement of phospholipids.
Moreover, the.se platelets have been shown to
enhance the conversion of prothrombin to
thrombin by a complex of purified coagula-
tion factors X, and V" in the presence of cal-
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cium. This catalytic activity appeared to be a
function of the amount of phosphatidy4senne
exposed at the ouler surface, when the assay
is performed with excess of coagulation fac-
tors [13]. Furthermore, platelets thus acti-
vated cause a draslic reduction ofthe clotting
time in a modified Stypven assay which has
been made insensitive to release of factor
V (VJ by the platelets [7].
Since prostacyciin is known to inhibit re-
lease ofall three granule constituents [14], its
anticoagulant property could be explained by
preventing release of factor V(V"). We were
interested to see ifprostacyclin also interferes
with the ability of platelets to generale a pro-
coagulant surface ofnegatively charged phos-
phoLipids.
Materials and Methods
Prostacyclin was a generous gift of Di. G. Horn-
s/ra. and was dissolved in I mMNaOH at the desired
concenlration. Aspirin (lysyl-form) and dibutyryl
cAMP were from Egic and Sigma, respectively. Colla-
gen type I was obtained from Hormon Chemie,
Miinchen. In.some experiments highly purified colia'
gen type I (generous gift of Prof. J. Caen, Paris) was
used, but this produced essentially the same results.
Blood coaguiation factors V", X" and prothrombin
were purified as described in Rosing et al. [15].
Thrombin-specific chromogenic substrate H-D-phe-
nylalanyl-Lpipecolyl-arginine-p-nitroanilide dihy-
dro-chloride (52238) was from AB Kabi Diagnostica,
Stockholm.
Blood was drawn from healthy male volunteers
and collected in acid-citrate-dextrose (ACD; 0.052 M
citric acid/0.08 M trisodium cirate/O.183 M gJucose;
I vol of ACD to 5 vol of blood). Platelet-rich plasma
was obtained following centrifugation at 200 g for
15 min at room temperature. Platelets were pelleled
from piatelet-rich plasma at 6009 for 15 min. The
platelet pellet was carefully resuspended in a buffer
containing 136nM NaCl, 2.7mM KCl, 2.0mM
MgClz, 25m-I1 glucose, l0ntM Hepes [4-(2-hy-
droxyethyl)-l-piperazine ethane sulphonic acidl and
0.0590 (w/v) fartS' acid free human serum albumin,
pH 6.6 (Hepes buffer). The platelets were washed
twice in this buffer by centrifugarion at 600 g for
15 min. Before each centrifugation I vol of ACD was
added to 15 vol of platelet suspension. Finally the
platelets were resuspended in Hepes bufler, pH 7.5, at
a cell count of i07 ml-r (Coulter counler).
Plarelet activation by collagen and thrombin and
measurement of platelet prothrombin converting ac-
tivity was carried out essentially as described before
[12. 13]. Brief ly: 290 pl ofthe platelet suspension was
activated in the presence of 15 pJ' 75 mM CaCl2 by
15 ld coilagen (200 irglml) and 5 pl thrombin
(125 n-Ln at 37 " C. 15 min after activation, 50 pl of a
freshly prepared mixlure containing 30 nM factor X"
and 60 n 41 lactor V" was added. 2 min later, the enzy-
matic reaction was started by addition of 125p1
16 pM prothrombin. After I min a sample was taken
and immediaiely diluted in a buffer containing
l20mM NaCl, 50 m.41 Tris and 2mM EDTA (pH
7.5) to stop the reaction. The amount of thrombin
formed was measured by the change in adsorbance at
405 nm per unit time produced by the action of
thrombin on 52238, and calcuiated from a calibration
curve made *'ith kno*n amounts of active-site-ti-
trated rhrombin.
The effect ofprostacyclin was measured by incuba-
tion ofplatelets with 5 pl prostacyclin (or 5 pl ofvehi-
cle as a control) for 30 s, prior to carrying out the acti-
valion procedure by collagen and thrombin. Incuba-
tions wirh dibutyryl cAMP and aspirin were done
analogously for 5 min, prior to platelet activation.
Platelet release and aggregation were measured in a
Chronolog lumi-aggregometer using fi refly luciferin-
luciferase to measure release of ATP [16]. The extent
of ATP released was determined by adding the frrefly
luciferin-luciferase reagent 5 min after platelet activa-
tion. This was done in order to avoid influence ofthe
ATP reagent on the aggregation behavior.
Results and Discussion
Addition of prostacyclin to platelels re-
sults in a dose-related inhibition of platelet
prothrombinase activity as evoked by treat-
ment with collagen plus thrombin (fig. 1, top
panel). Half-maximal inhibition was ob-
served at a prostacyclin concentration of
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10ng/m1. This is approximately 3 times
higher than required to produce half-maxi-
mal inhibition of platelet aggregation and re-
lease (data not shown), and of the same order
as required to inhibit platelet adhesion to col-
lagen [20]. No inhibition was observed when
prostacyclin was added after the activation
procedure. The inhibitory activity of prosta-
cyclin might be related to its ability to in-
crease cyclic AMP concentrations in platelets
Fig. l. Platelet prothrombinase
activity generated by treatment with
collagen plus thrombin in the pres-
enc€ of prostacyclin, dibutyryl
cAMP or aspirin. Activity is ex-
pressed as percentage ofactivity ob-
served in the absence ofinhibitors.
[17J. Treatment of platelets with dibutyryl-
cAMP also produces dose-related inhibition
of platelet prothrombinase activity, being
half-maximal at 800 UM (fie.1, middle pan-
el). In order to check ifthe inhibitory effect of
prostacyclin would depend on decreased
thromboxane A2 production of the platelets,
the effect of aspirin was also measured. Aspi-
rin up to 3 mglml was completely unabie to
inhibit plateler prothrombinase activit-v
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(fig. 1, bottom panel). This concentralion is
n:ore than sufficient 1o produce a complele
inhibition of malon-dialdeh-vde production
b.v treatment of platelets with collagen and
thrombin (data not shown). This suggests
that thromboxane A2 formation is not re-
quired to evoke platelet prothrombinase ac-
iir.it-v.
Srnce the assay procedure critically de-
pends on the presdnce of negatively charged
phospholipid while factor V" is not rate-lim-
iting. the data suggest that prostacyclin is able
to inhibit exposure of phosphatidylserine at
the piatelet outer surfbce. This would also
explain why prostacyclin is able to inhibit
factor X activation by factors IX" and VIII'
in the presence ofplatelets [18]. These effects
of prostacyclin may very well be responsibie
for the observation that in the absence of
heparin, biood clotting during haemodiaiysis
can be efliciently prevented by prostacyclin
[9]. Since prostacyclin has no direct effect
on coagulation factors, its potent anticoagu-
lant action is presurnably exercised via inhi-
biiion of pl'atelet activation, not only on fac-
tor V release but also on the exposure of a
procoagulant phospholipid surface. Finally,
the inhibition by aspirin of so-called plateiet
factor-3 activity in a clotting assay as ob-
served by olhers [2J, is presumably caused
only by inhibition of release of factor V from
platelets, rather than by inhibiting exposure
of procoagulant phospholipids.
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